• AngioDynamics reported a Q2 2025 EPS of -$0.26, which was lower than the estimated -$0.11.
• The company's revenue reached $72.8 million, indicating strong sales performance despite financial challenges.
• Med Tech division saw a 25% increase in revenue, driven by key products and FDA clearance of NanoKnife for prostate cancer treatment.

AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company that specializes in the development and sale of innovative medical devices. The company operates in the healthcare sector, focusing on vascular access, peripheral vascular disease, and oncology. AngioDynamics competes with other medical technology firms, striving to deliver advanced solutions for patient care.

On January 8, 2025, AngioDynamics reported an earnings per share (EPS) of -$0.26, which was lower than the estimated -$0.11. However, the company generated a revenue of approximately $72.8 million, surpassing the estimated $70.6 million. This indicates that while the company faced challenges in profitability, it managed to exceed revenue expectations.

The Med Tech division was a standout performer, achieving a 25% increase in revenue. This growth was driven by the strong market performance and acceptance of key products such as Auryon, AlphaVac, and AngioVac. Additionally, the NanoKnife received FDA clearance and showed promising results in clinical trials for prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.

Despite a negative price-to-earnings (P/E) ratio of -2.36 and a negative earnings yield of -42.44%, AngioDynamics' stock surged by 35% following the earnings report. The company's current ratio of nearly 1.98 reflects its ability to cover short-term liabilities with its short-term assets, indicating a stable liquidity position. However, the enterprise value to operating cash flow ratio of -20.24 highlights ongoing challenges in generating positive cash flow from operations.